mHealth-Supported Intervention Boosts Physical Activity in Adults With Newly Diagnosed Diabetes
By Lori Solomon HealthDay Reporter
TUESDAY, April 8, 2025 -- A mobile health (mHealth)-supported home-delivered physical activity (PA) intervention is feasible and effective at promoting sustained, purposeful exercise in adults with newly diagnosed diabetes, according to a study published online March 26 in BMJ Open.
Katie Hesketh, Ph.D., from University of Birmingham in the United Kingdom, and colleagues assessed the feasibility of an mHealth-supported home-delivered PA intervention (MOTIVATE-T2D) in adults with recently diagnosed type 2 diabetes. The analysis included 125 participants randomly assigned (1:1) to intervention (MOTIVATE-T2D) or active control groups.
The researchers found that MOTIVATE-T2D participants were more likely to start (odds ratio [OR], 10.4) and maintain purposeful exercise at six (OR, 7.1) and 12 months (OR, 2.9). An exploratory analysis showed a potential effect in favor of MOTIVATE-T2D, including proposed primary outcomes hemoglobin A1c (HbA1c) and systolic blood pressure in a future randomized controlled trial (between-group mean differences: HbA1c at six months, −5 percent change from baseline; HbA1c at 12 months, −2 percent change from baseline; systolic blood pressure at six months, −1 mm Hg; systolic blood pressure at 12 months, −4 mm Hg).
"The results from this trial suggest that the MOTIVATE-T2D approach of using biometrics from wearable technologies to support a home-delivered, personalized behavioral counseling service was promising for the promotion, uptake, and adherence to purposeful exercise in people with newly diagnosed type 2 diabetes," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
Many Medicaid Enrollees Have Restricted Access to SGLT2 Inhibitors, GLP-1 Receptor Agonists
WEDNESDAY, April 30, 2025 -- Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2...
Sodium-Glucose Cotransporter 2 Inhibitors Increase Risk for Falls in Patients With Diabetes
WEDNESDAY, April 30, 2025 -- Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes, according to a study...
GLP-1 RAs, SGLT2 Inhibitors May Reduce Risk for Alzheimer Disease, Dementia in T2DM
THURSDAY, April 17, 2025 -- Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a reduced risk...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.